LuminUltra Acquires Legionella Testing Business from Genomadix and Inks Strategic License to Commercialize Additional Tests for Ultra-portable Molecular Diagnostic Platform
9.9.2024 14:00:00 EEST | Business Wire | Press release
LuminUltra (luminultra.com), the global leader in applied molecular diagnostics, today announced the acquisition of the legionella testing business assets of Genomadix Inc (genomadix.com), along with rights to develop and commercialize further assays and test methods in water, energy and food and beverage markets globally using the Genomadix Cube™ qPCR (quantitative polymerase chain reaction) Platform.
With this transaction, LuminUltra further expands its industry-leading portfolio of molecular testing solutions for rapid identification and quantification of the microbes within residential, commercial and industrial water systems that are responsible for causing the potentially deadly Legionnaire’s disease.
When paired with its easy-to-use automated test kit, the Genomadix Cube thermocycling platform will generate results that measure the presence and quantity of Legionella contamination in under one hour with laboratory-grade sensitivity. The elegant simplicity of the system allows any user in the field to quickly and accurately assess the level of contamination within their water system and take the actions necessary to minimize risk of outbreaks and operational downtime.
The industry leading legionella detection toolkit
“With this latest addition to our portfolio, we can now help even more customers around the world to rapidly and accurately monitor and manage against the proliferation of harmful Legionella bacteria,” said Pat Whalen, LuminUltra CEO. “This rapid, point of use solution complements our existing GeneCount® laboratory qPCR workflow and mail-in sample testing offerings by providing a best-in-class solution for those time sensitive, ‘in-field’ use cases that demand near-real-time and accurate results to confidently inform critical operational decisions and actions.”
Steve Edgett, CEO of Genomadix, added, “LuminUltra was the perfect home for the Legionella business that we nurtured under the Spartan Bioscience brand. We intend to support a seamless transition with our customers. We are thrilled that LuminUltra will bring scale, expertise, and focus to the Legionella business. Genomadix is focused on the development and commercialization of precision medicine tests on the Cube and licensing our CubeX Open Platform to strategic partners. This agreement is a win-win as LuminUltra will lead the development of new tests and expanded access to fast and accurate qPCR testing on CubeX for time-sensitive point of use applications in applied markets.”
The transaction was completed on July 31, 2024.
About LuminUltra
Founded in 1995, LuminUltra is a biological diagnostic testing company headquartered in Canada with operations in six countries. Widely recognized as the global leader in applied molecular diagnostics for the water, energy and food & beverage markets, it was also a key supplier of COVID-19 clinical testing reagents to the Government of Canada. Customers in over 80 countries trust LuminUltra’s technology, production reliability and history of customer service excellence to deliver their essential services in a safe-state. At the same time, LuminUltra fosters a culture of innovation and agility and is on an accelerated growth path, acquiring multiple companies in recent years and forming a partnership with the specialized private equity firm XPV Water Partners.
About Genomadix
Based in Ottawa, Canada, Genomadix Inc. is a pioneer in real-time qPCR point of need technology. The Genomadix Cube is a molecular diagnostic instrument capable of performing tests for precision medicine genotyping on a sample-to-result platform. The portable size, ease of use, and on-demand processing capability enables users to generate time-critical results in approximately one hour. The Cube platform is also available as an open platform called CubeX that can be used to design, develop and run any qPCR test for research and product development use. Applications of the Genomadix Cube technology include but are not limited to precision medicine, clinical and environmental. For more information, visit www.genomadix.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240909727336/en/
Contacts
Media: Gene Schilling, Director of Marketing
gene.schilling@luminultra.com +1-519-990-0084
Media: Chelsey Martellacci, Marketing Manager
media@genomadix.com 1-888-810-7788
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
IQM Announces Novel Quantum Error Correction Approach Toward Fault-Tolerant Quantum Computing9.6.2026 10:00:00 EEST | Press release
IQM Quantum Computers, the global leader in superconducting quantum computers, has developed a novel quantum error-correcting code that achieves up to three orders of magnitude lower logical error rates than the surface code, also requiring up to eight times fewer physical qubits. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260609533201/en/ IQM´s breakthrough technology, called barbell codes. Unlike many alternative high-performance quantum error-correction approaches, the new code also maintains a comparatively low hardware complexity, marking a significant advancement toward scalable fault-tolerant quantum computing. Quantum error correction remains one of the defining challenges in the race toward practical quantum computing. Errors introduced by noise must be corrected faster than they accumulate, a requirement that previous approaches demanded either complex hardware or significant performance trade-offs, which IQM's
Longpoint Expands into Germany and the Netherlands, Targeting €400 Million of Infill Logistics Investment9.6.2026 10:00:00 EEST | Press release
Longpoint Partners today announced its expansion into Germany and the Netherlands, extending its infill industrial strategy into two of Europe’s most supply-constrained logistics markets. The firm is establishing a presence in high-demand locations, including Düsseldorf, Frankfurt, and the Randstad, and plans to deploy approximately €400 million into logistics assets near major population centers and transportation corridors. “We are excited to expand Longpoint’s infill industrial strategy into Germany and the Netherlands,” said Dwight Angelini, Founding and Managing Partner of Longpoint Partners. “These are highly attractive logistics markets with strong fundamentals, limited supply, and a clear need for high-quality light industrial and logistics space. With Gijs and Benedict leading our local efforts, we have the market knowledge, relationships, and discipline to identify attractive opportunities and execute with conviction.” The expansion extends Longpoint’s focus on infill logisti
ISO/TC 251 Recognizes Ampowr as the Only BESS Operator With a Fully Integrated ISO Stack9.6.2026 10:00:00 EEST | Press release
ISO/TC 251, the international technical committee that authors the ISO 55000 family of asset management standards, has published a case study profiling Ampowr's integrated certification methodology. Authored by NEN, the Dutch national standards body, the study is now publicly available in the ISO/TC 251 case studies library alongside profiles of Rijkswaterstaat, the US Army Corps of Engineers, Novo Nordisk, and Veolia. ISO/TC 251 approached Ampowr directly. NEN subsequently conducted an in-depth interview with Executive Director Andrew Elwell, examining how Ampowr operates its five certifications (ISO 9001, ISO 14001, ISO 45001, ISO 27001 and ISO 55001), as a single integrated system rather than separate compliance silos. "To our knowledge we are the only provider globally with this complete value stack visible in the market," said Andrew Elwell, Executive Director of Ampowr. "We have actively sought a peer that holds BESS hardware, energy management software, energy trading and asset
Estonia Raises the Bar for Secure Digital Identity in Europe With New eID Cards Developed With Thales9.6.2026 10:00:00 EEST | Press release
With increasing cyber risks and the rapid evolution of digital public services, Estonia is reinforcing the security, durability and adaptability of the documents that underpin its digital society: identity cards, residence permit cards, e-resident digital identity cards, diplomatic identity cards, certificates of AIP (Applicant for International Protection). Backed by Thales’ decades of expertise in secure identity technologies, the new programme introduces stronger protection against fraud, upgraded electronic features and the ability to respond quickly to emerging cybersecurity threats. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260608624209/en/ © Reelika Riimand - Estonian Police and Border Guard Board At the heart of the programme is Estonia’s new national eID card, designed by Thales to blend strong physical protectionwith robust digital security. Its materials, visual features and advanced security techniques make
Bial Reports Topline Results From ACTIVATE Phase 2b Study in GBA‑Associated Parkinson’s9.6.2026 09:00:00 EEST | Press release
Bial, an innovation-driven biopharmaceutical company focused on neurosciences and rare diseases, announced today that the Phase 2b ACTIVATE study of BIA 28-6156 (pariceract) in patients with Parkinson’s who have a pathogenic variant in the GBA1 gene (GBA-PD) did not meet its primary, nor the key secondary efficacy endpoints, meaning that BIA 28-6156 failed to slow the progression of GBA-PD versus placebo. BIA 28-6156 proved to be generally well tolerated in the study, with no unexpected safety concerns arising. While the study data provide valuable scientific information and contribute to a broader understanding of Parkinson’s biology, BIA 28-6156 did not demonstrate significant differentiation from placebo on the primary or key secondary endpoints measured. Based on the lack of demonstrated efficacy in this study, Bial has made the decision to discontinue further development of BIA 28-6156 for this indication. “We are disappointed with the outcome of the Phase 2b ACTIVATE study, as th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom